Navigation Links
Perle BioScience Selects BlazeFund As Its Crowd Funding Platform
Date:9/4/2013

BOSTON, Sept. 4, 2013 /PRNewswire/ -- BlazeFund, a new equity crowd funding company in Boston, Massachusetts, has listed the first biotech company on their platform. Atlanta-based Perle BioScience is a life sciences company whose mission is to address patient needs that have been considered "impossible" to tackle.

(Logo: http://photos.prnewswire.com/prnh/20130808/CG60459LOGO)

Perle BioScience's founder, Dr. Claresa Levetan, is internationally recognized as a leader of diabetes research. She previously co-founded CureDM and was a lead inventor of a therapeutic drug for the reversal of diabetes. CureDM's IP portfolio was licensed to Sanofi in 2010 for upfront and commercial milestone payments of a potential value totaling $335M.

Dr. Levetan is raising capital for Perle BioScience to "pave the way for a revolutionary therapeutic treatment which will create a transformational shift in the treatment of diabetes," states Dr. Levetan. According to the American Diabetes Association, there are currently 26 million diabetes patients in the US.

Dr. Levetan indicates, "Nearly 1 out of 10 healthcare dollars or 4 out of 10 Medicare dollars are spent on patients with diabetes. As health care costs are spiraling and the diabetes population is growing, Perle BioScience is looking to address the underlying mechanisms that cause diabetes. Our treatment will be a huge benefit to society as a whole – not just for diabetic patients - but also in terms of managing healthcare costs."

Perle BioScience elected to utilize equity crowd funding to obtain the company's growth capital. Dr. Levetan mentions, "Perle is making a paradigm shift in the treatment of diabetes, and we specifically chose equity crowd funding, which is a perfect fit, since it is creating a paradigm shift as it relates to accessing capital. The ability to expose our company's technology to so many types of investors, from small to large, is invaluable. More importantly, we specifically selected BlazeFund based on their healthcare/ life science focus and the experience of their leadership team."

Aaron Sanders, CEO of BlazeFund, adds, "BlazeFund provides the entire investment community with exposure and access to innovative ventures. We are very proud and enthusiastic to be working with an industry leader that has the caliber of Perle BioScience."

For more information about BlazeFund please contact:
Aaron Sanders, CEO & Founder
aaron@blazefund.com


'/>"/>
SOURCE BlazeFund
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 150,000 Medical Professionals Stay Paperless with Practice Fusion
2. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
3. Whats New with Flu this Season: Industry Recommendations, New Vaccines and 100% Paperless Flu Program Solution
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
6. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
7. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
8. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
9. Sangamo BioSciences to Acquire Ceregene
10. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
11. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... The global  active pharmaceutical ingredients (API) market  is ... on a new report by Grand View Research, Inc. The rising prevalence ... market over the forecast period. Advancements in recombinant molecular technologies and high ... Continue Reading ... ...
(Date:1/24/2017)... , January 24, 2017 Aptuit, ... Molecular Surgical Laboratory des Massachusetts General Hospital (MGH) unter ... geht es um die Identifizierung und Validierung neuartiger Targets ... dass sie der Resistenz von Antibiotika bei der Behandlung ... ...
(Date:1/24/2017)... , Jan. 23, 2017 Laboratory Markets ... global use of mass spectrometry in both clinical and ... ,MS analysis, global market size of $6.8 billion and ... next four years, profiles the use of mass spectrometry ... 21 countries. This study investigated growth in the use ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... Attention women who want bigger ... that autologous fat grafting—taking one’s own fat and putting it in other body ... , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & Laser ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... the following statement on the imposition of the Mexico City Policy, also known ... policy, enacted again today through Executive action, prohibits foreign non-governmental organizations from receiving ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... support them, Dr. Carol Francis, Psychologist in the South Bay area , ... respectful governing for all people and by all people shines as a bright ...
(Date:1/23/2017)... ... January 23, 2017 , ... PKF O’Connor Davies , LLP, the nation’s ... accountant at the Firm, will participate in the 40th Annual "Empire State Building Run ... race up 1,576 steps, a vertical distance equal to about a fifth of a ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... standards for healthcare treatment providers who treat the full spectrum of eating disorder ... , The Presidents Council consists of the leading eating disorder treatments centers located ...
Breaking Medicine News(10 mins):